Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic agent for cancer

a cancer and therapeutic agent technology, applied in the field of cancer therapeutic agents, can solve the problems of many side effects of anticancer agents, and achieve the effects of reducing the risk of infectious diseases, and avoiding the reduction of immune cells

Inactive Publication Date: 2010-09-30
TAKARA HOLDINGS +1
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0027]According to the present invention, a method of treating cancer and a cancer therapeutic agent, which activate cellular immunity against cancer and have a high therapeutic effect is provided. A treatment method for imparting damage to cancer cells including an anticancer agent damages the cancer cells to release a large amount of tumor antigens into the body. The lymphocytes which are administered under these situations cause an immunoresponse to the released tumor antigen, thereby acquiring the cytotoxicity against the cancer cells. In other words, the lymphocytes to be administered are a not yet known anticancer agent that functions as a new vaccine therapy. Moreover, the treatment method and the therapeutic agent can reduce the risk of infectious diseases because a decrease in immunity due to the reduction in lymphocytes can be avoided.

Problems solved by technology

Many of anticancer agents have a lot of side effects because they damage not only cancer cells but also normal cells actively proliferating.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Studies on Effects of Transferred T Cells after Administration of Anticancer Agent Using Syngeneic Mouse Tumor Model

(1) Preparation of Highly Metastatic B16F10 Cells

[0071]A mouse melanoma B16F10 cell line (provided by Institute of Development, Aging and Cancer, Tohoku University) is administered to 7-week old female C57BL / 6 mice (available from Japan SLC, Inc.) via a tail vein under anesthesia, and lung metastasis tumor is collected 14 days later. The collected tumor is dispersed into a single cell, and the resulting cells are cultured in vitro, then administered to mice again. This procedure is repeated three times. When 1×105 cells are finally administered, highly metastatic B16F10 cells (hereinafter referred to as hB16F10) showing lung metastasis of about 50 to 100 cells after 14 days of culture are obtained.

(2) Preparation of Splenic Lymphocytes from Cancer-Bearing Mouse

[0072]The hB16F10 is suspended in Dulbecco's phosphate buffered saline (manufactured by Baxter International I...

example 2

Expansion of Lymphocytes from Peripheral Blood Mononuclear Cell (PBMC) of Cancer Patient-1

(1) Separation of PBMC and Inactivated Plasma

[0077]Heparin-added blood sample was collected in a volume of 50 to 58 mL from a donor of a human cancer patient with informed consent, and the obtained blood was centrifuged at 700×g for 20 minutes. After the centrifugation, the supernatant plasma fraction and the PBMC-containing cell fraction were respectively collected. The plasma fraction was inactivated at 56° C. for 30 minutes and centrifuged at 900×g for 30 minutes. The supernatant after the centrifugation was collected as an inactivated plasma and subjected to each experiment. The PBMC-containing cell fraction was diluted with DPBS and overlaid on Ficoll-paque (manufactured by GE Healthcare Bio-Sciences), and then centrifuged at 700×g for 20 minutes. The intermediate layer of the PBMC was collected with a pipette, washed, and the viable cell count was calculated using an automated blood cell ...

example 3

Expansion of Lymphocytes from PBMCs of Cancer Patient-2

(1) Immobilization of OKT3 and CH-296

[0087]In a similar manner to item (2) of Example 2, the OKT3 and the CH-296 were immobilized to the culture equipment used in the following experiment.

(2) Expansion of Lymphocytes

[0088]In a similar manner to item (3) of Example 2, the expansion of the lymphocytes was carried out, except that the basal medium used for culturing was GT-T503 containing 0.2% human HSA (hereinafter referred to as 0.2% HSA / GT-T503), the medium used at the start of culture and on day 4 of culture was 0.2% HSA / GT-T503 containing 0.6% autologous plasma derived from cancer patients, and the medium used on days 7 and 10 of culture was plasma-free 0.2% HSA / GT-T503. On day 10 of culture, the viable cell count was counted using an automated blood cell counting device to calculate the expansion fold in comparison with the cell count at the start of culture. The results are shown in Table 8.

TABLE 8CancerPatientExpansion Fold...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
pHaaaaaaaaaa
volumeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a method for treatment of cancer, which comprises the following steps (A) and (B): (A) applying a treatment which induces the reduction in lymphocytes to a patient; and (B), subsequent to step (A), administering lymphocytes to the patient promptly. The present invention also relates to a cancer therapeutic agent and a cancer treatment kit for use in the method. When the method is used as an immunoreconstructive therapy, the decrease in immunologic competence which may be caused by the reduction in lymphocytes can be avoided and, therefore, the risk of the occurrence of an infectious disease can be decreased.

Description

TECHNICAL FIELD[0001]The present invention relates to a cancer therapeutic agent and a treatment method, which are useful in the medical field.BACKGROUND ART[0002]An operative therapy, a radiotherapy, a chemotherapy, an immunotherapy (a cell therapy or a vaccine therapy), etc. have been used for the cancer therapy. Among them, a chemotherapy with an anticancer agent is common. Many of anticancer agents have a lot of side effects because they damage not only cancer cells but also normal cells actively proliferating. For example, a side effect that is called a hematologic toxicity due to bone marrow suppression can be caused, and, as a result, neutrophils, platelets, lymphocytes, etc. in the peripheral blood are decreased below the normal value. In such a case, it is effective to repeat administration with a certain convalescent period so that anticancer agents in as large amount as possible may be administered, while suppressing the side effect to the minimum, and thus this method ha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/00A61K35/12C12N5/00A61P35/04A61K35/14
CPCA61K35/14A61K45/06A61K39/0011C12N5/0636C12N2501/2302A61K2300/00A61P35/00A61P35/04A61K39/4611A61K2239/26A61K2239/31A61K2239/57A61K39/46449A61K2239/38
Inventor SHIKU, HIROSHIKAGEYAMA, SHINICHIKITANO, SHIGEHISAIDENO, MITSUKOTOMITA, KEISUKEENOKI, TATSUJITAKESAKO, KAZUTOHKATO, IKUNOSHIN
Owner TAKARA HOLDINGS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com